journal
https://read.qxmd.com/read/38530606/rebistart-adherence-of-patients-with-multiple-sclerosis-to-treatment-with-subcutaneous-interferon-beta-in-the-context-of-a-patient-support-program
#1
JOURNAL ARTICLE
Matthias Schwab, Andrew Chan, Anna-Katharina Eser, Boris Kallmann, Dieter Pöhlau, Joachim Richter, Torsten B Wagner, Christoph Grothe
INTRODUCTION: Treatment adherence is a critical success factor in the disease-modifying therapy (DMT) of multiple sclerosis (MS). The REBISTART study prospectively evaluated adherence in patients using components of a patient support program (PSP). METHODS: The 12-month non-interventional multicenter study examined the real-world adherence to subcutaneously (sc) injected interferon beta-1a (Rebif® ). Patient-assessed adherence was measured by a visual analog scale (VAS) and the Morisky Medication Adherence Scale (MMAS)...
March 26, 2024: Neurology and Therapy
https://read.qxmd.com/read/38530605/anti-n-methyl-d-aspartate-receptor-encephalitis-in-people-living-with-hiv-case-report-and-literature-review
#2
REVIEW
Jiangjin Hui, Jinhua Wang, Zhikai Wan, Qing Cao, Bohao Dai, Haiyan Lou, Biao Zhu
With the increase in the number of cases of autoimmune encephalitis (AE), the cerebrospinal fluid (CSF) of people living with HIV (PLWH) showing abnormal behavior, cognitive impairment or abnormal movements should be actively screened for the antibody panel of AE. Early recognition and treatment can prevent severe seizures or coma and markedly improve the prognosis of patients. The first-line immunotherapy for AE includes intravenous methylprednisolone and immunoglobulin. However, whether long-time immunosuppressive maintenance therapy is needed is debated...
March 26, 2024: Neurology and Therapy
https://read.qxmd.com/read/38512694/impact-of-baseline-neuropathy-severity-on-vutrisiran-treatment-response-in-the-phase-3-helios-a-study
#3
JOURNAL ARTICLE
Marco Luigetti, Dianna Quan, John L Berk, Isabel Conceição, Yohei Misumi, Chi-Chao Chao, Shaun Bender, Emre Aldinc, John Vest, David Adams
INTRODUCTION: Hereditary transthyretin (ATTRv, v for variant) amyloidosis is a rare, progressive, fatal disease with multisystem manifestations, caused by pathogenic variants in the transthyretin (TTR) gene. Vutrisiran, an RNA interference therapeutic that results in rapid TTR knockdown, improved neuropathy and quality of life (QOL) versus external placebo in patients with ATTRv amyloidosis with polyneuropathy in the phase 3 HELIOS-A study (NCT03759379). This post hoc analysis evaluates the impact of baseline neuropathy severity on response to vutrisiran treatment...
March 21, 2024: Neurology and Therapy
https://read.qxmd.com/read/38502463/publisher-correction-summary-of-research-what-is-the-true-impact-of-cognitive-impairment-for-people-living-with-multiple-sclerosis-a-commentary-of-symposium-discussions-at-the-2020-european-charcot-foundation
#4
Sarah A Morrow, Paola Kruger, Dawn Langdon, Nektaria Alexandri
No abstract text is available yet for this article.
March 19, 2024: Neurology and Therapy
https://read.qxmd.com/read/38498263/correction-neurofilament-light-chain-in-adult-and-pediatric-multiple-sclerosis-a-promising-biomarker-to-better-characterize-disease-activity-and-personalize-ms-treatment
#5
Angelo Ghezzi, R F Neuteboom
No abstract text is available yet for this article.
March 18, 2024: Neurology and Therapy
https://read.qxmd.com/read/38488979/holistic-long-term-management-of-people-with-relapsing-multiple-sclerosis-with-cladribine-tablets-expert-opinion-from-france
#6
REVIEW
Jonathan Ciron, Bertrand Bourre, Giovanni Castelnovo, Anne Marie Guennoc, Jérôme De Sèze, Ali Frederic Ben-Amor, Carine Savarin, Patrick Vermersch
Cladribine tablets (CladT) has been available for therapeutic use in France since March 2021 for the management of highly active relapsing multiple sclerosis (RMS). This high-efficacy disease-modifying therapy (DMT) acts as an immune reconstitution therapy. In contrast to most high-efficacy DMTs, which act via continuous immunosuppression, two short courses of oral treatment with CladT at the beginning of years 1 and 2 of treatment provide long-term control of MS disease activity in responders to treatment, without the need for any further pharmacological treatment for several years...
March 15, 2024: Neurology and Therapy
https://read.qxmd.com/read/38451463/assessing-the-long-term-48-week-effectiveness-safety-and-tolerability-of-fremanezumab-in-migraine-in-real-life-insights-from-the-multicenter-prospective-friend3-study
#7
JOURNAL ARTICLE
Piero Barbanti, Gabriella Egeo, Stefania Proietti, Florindo d'Onofrio, Cinzia Aurilia, Cinzia Finocchi, Laura Di Clemente, Maurizio Zucco, Alberto Doretti, Stefano Messina, Massimo Autunno, Angelo Ranieri, Antonio Carnevale, Bruno Colombo, Massimo Filippi, Miriam Tasillo, Steno Rinalduzzi, Pietro Querzani, Giuliano Sette, Lorenzo Forino, Francesco Zoroddu, Micaela Robotti, Alessandro Valenza, Cecilia Camarda, Laura Borrello, Marco Aguggia, Giovanna Viticchi, Carlo Tomino, Giulia Fiorentini, Bianca Orlando, Stefano Bonassi, Paola Torelli
INTRODUCTION: Long-term (1-year) fremanezumab treatment proved to be effective, safe, and well tolerated in individuals with migraine and < 2 medication clusters in a randomized controlled trial (RCT). We aimed to assess real-world evidence (RWE), long-term effectiveness, tolerability, and safety of fremanezumab in people with high-frequency episodic migraine (HFEM) or chronic migraine (CM) with > 3 treatment failures and various comorbidities. METHODS: A 48-week, prospective, multicenter (n = 26), cohort study assessed fremanezumab's effectiveness, safety, and tolerability in consecutive adults with HFEM or CM with > 3 treatment failures...
March 7, 2024: Neurology and Therapy
https://read.qxmd.com/read/38446379/impact-of-immune-cells-on-stroke-limited-to-specific-subtypes-evidence-from-mendelian-randomization-study
#8
JOURNAL ARTICLE
Chen Chen, Qi Liu, Yao Li, Jingwen Yu, Shudi Wang, Li Liu
INTRODUCTION: Stroke is one of the common diseases that pose a severe threat to human health, with immune cells playing a crucial role in its onset and recovery. However, the specific mechanisms and causal relationships of different immune cell groups in various clinical stroke subtypes are unclear. This study explored the causal relationship between immune cells and stroke and its subtypes using Mendelian randomization (MR) analysis. METHODS: Data from genome-wide association studies were analyzed using inverse-variance weighted (IVW), MR-Egger, and weighted median methods for MR analysis, along with heterogeneity tests, sensitivity analysis, and pleiotropy analysis...
March 6, 2024: Neurology and Therapy
https://read.qxmd.com/read/38430355/assessment-of-barriers-to-referral-and-appointment-wait-times-for-the-evaluation-of-spinal-muscular-atrophy-sma-findings-from-a-web-based-physician-survey
#9
JOURNAL ARTICLE
Mary A Curry, Rosángel E Cruz, Lisa T Belter, Mary K Schroth, Jill Jarecki
BACKGROUND: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease characterized by progressive muscle weakness and atrophy. Clinical trial data suggest early diagnosis and treatment are critical. The purpose of this study was to evaluate neurology appointment wait times for newborn screening identified infants, pediatric cases mirroring SMA symptomatology, and cases in which SMA is suspected by the referring physician. Approaches for triaging and expediting referrals in the US were also explored...
March 2, 2024: Neurology and Therapy
https://read.qxmd.com/read/38427274/the-association-between-national-institutes-of-health-stroke-scale-score-and-clinical-outcome-in-patients-with-large-core-infarctions-undergoing-endovascular-treatment
#10
JOURNAL ARTICLE
Lingyu Zhang, Jinfu Ma, Mengmeng Wang, Lin Zhang, Wenzhe Sun, Honghong Ji, Chengsong Yue, Jiacheng Huang, Wenjie Zi, Fengli Li, Changwei Guo, Pengfei Wang
INTRODUCTION: This study aimed to analyze the association between baseline National Institutes of Health Stroke Scale (NIHSS) scores and clinical outcomes in patients with large core infarctions undergoing endovascular treatment (EVT), a relationship that remains unclear. METHODS: Data were obtained from the MAGIC study, a prospective multicenter cohort study focusing on patients with acute large core ischemic stroke. This analysis evaluated the impact of NIHSS scores on EVT outcomes in patients with large core infarctions...
March 1, 2024: Neurology and Therapy
https://read.qxmd.com/read/38427273/constructing-and-validating-a-nomogram-model-for-short-term-prognosis-of-patients-with-achr-ab-gmg
#11
JOURNAL ARTICLE
Feng Liang, Zhaoxu Yin, Yaqian Li, Guanxi Li, Jing Ma, Huiqiu Zhang, Xiaoqian Xia, Make Yao, Xiaomin Pang, Juan Wang, Xueli Chang, Junhong Guo, Wei Zhang
OBJECTIVE: This study aimed to establish and validate a nomogram prognostic model for predicting short-term efficacy of acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (GMG). METHODS: A retrospective observational study was conducted at the First Hospital of Shanxi Medical University, enrolling patients diagnosed with AChR-Ab+ GMG from May 2020 to September 2022. The primary outcome was the change in the Myasthenia Gravis Foundation of America (MGFA) post-intervention status after 6 months of standard treatment...
March 1, 2024: Neurology and Therapy
https://read.qxmd.com/read/38376607/summary-of-research-what-is-the-true-impact-of-cognitive-impairment-for-people-living-with-multiple-sclerosis-a-commentary-of-symposium-discussions-at-the-2020-european-charcot-foundation
#12
JOURNAL ARTICLE
Sarah A Morrow, Paola Kruger, Dawn Langdon, Nektaria Alexandri
Cognitive symptoms affect disease management and activities of daily living for people living with multiple sclerosis (MS). This summary of research article summarises previously published discussions ('What is the true impact of cognitive impairment for people living with multiple sclerosis? A commentary of symposium discussions at the 2020 European Charcot Foundation') from the 2020 European Charcot Foundation meeting between a patient expert living with MS, a neuropsychologist and a neurologist about the impact of cognitive impairment on people living with MS...
February 20, 2024: Neurology and Therapy
https://read.qxmd.com/read/38367176/monitoring-of-perioperative-microcirculation-dysfunction-by-near-infrared-spectroscopy-for-neurological-deterioration-and-prognosis-of-aneurysmal-subarachnoid-hemorrhage-an-observational-longitudinal-cohort-study
#13
JOURNAL ARTICLE
Shunyan Yang, Binbin Tan, Jie Lin, Xia Wang, Congying Fu, Kaishan Wang, Jinyu Qian, Jin Liu, Jishu Xian, Liang Tan, Hua Feng, Yujie Chen, Lihua Wang
INTRODUCTION: No evidence has established a direct causal relationship between early microcirculation disturbance after aneurysmal subarachnoid hemorrhage (aSAH) and neurological function prognosis, which is the key pathophysiological mechanism of early brain injury (EBI) in patients with aSAH. METHODS: A total of 252 patients with aSAH were enrolled in the Neurosurgical Intensive Care Unit of Southwest Hospital between January 2020 and December 2022 and divided into the no neurological deterioration, early neurological deterioration, and delayed neurological deterioration groups...
February 17, 2024: Neurology and Therapy
https://read.qxmd.com/read/38361080/safety-and-tolerability-of-combining-cgrp-monoclonal-antibodies-with-gepants-in-patients-with-migraine-a-retrospective-study
#14
JOURNAL ARTICLE
Taoufik Alsaadi, Reem Suliman, Vanessa Santos, Ibrahim Al Qaisi, Princess Carmina, Batool Aldaher, Shadi Haddad, Yazan Bader
INTRODUCTION: The introduction of clacitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has revolutionized the treatment of migraines. In clinical practice gepants might be considered as a valid option to treat acute attacks in patients with migraine who are treated with mAbs. However, the safety and tolerability of such a combination is not well addressed in the real-world setting. We designed this study to evaluate the safety and tolerability of combining CGRP mAbs with gepants in the management of migraines...
February 15, 2024: Neurology and Therapy
https://read.qxmd.com/read/38345742/understanding-the-symptoms-and-impacts-experienced-by-people-with-relapsing-remitting-ms-a-qualitative-investigation-using-semi-structured-interviews
#15
JOURNAL ARTICLE
Amy Barrett, Oyebimpe Olayinka-Amao, Tjalf Ziemssen, Trishna Bharadia, Christian Henke, Paul Kamudoni
INTRODUCTION: Multiple sclerosis (MS) is a disabling disease with unpredictable clinical manifestations. As clinical assessments may not fully capture the impact of MS on quality of life, they can be complemented by patient-reported outcome (PRO) measures to provide a more comprehensive picture of MS disease state and impact. The objectives of this study were to explore the experiences of people with relapsing-remitting MS, including symptoms and impacts on daily life, and to provide a conceptual model of MS outcomes...
February 12, 2024: Neurology and Therapy
https://read.qxmd.com/read/38345741/dyskinesia-and-pain-in-advanced-parkinson-s-disease-post-hoc-analysis-from-the-phase%C3%A2-3b-open-label-randomized-dyscover-study
#16
JOURNAL ARTICLE
Eric Freire-Alvarez, Paola Vanni, Egon Kurča, Lydia Lopez-Manzanares, Norbert Kovács, Cleanthe Spanaki, Tianming Gao, Lars Bergmann, Olga Sánchez-Soliño
INTRODUCTION: The DYSCOVER study was a phase 3b, open-label, randomized trial (NCT02799381) that evaluated levodopa-carbidopa intestinal gel (LCIG) versus optimized medical treatment (OMT) in patients with Parkinson's disease (PD) and a high burden of dyskinesia at baseline (defined as Unified Dyskinesia Rating Scale [UDysRS] total score ≥ 30). At week 12, patients receiving LCIG versus OMT experienced significant improvements in dyskinesia, pain, and health-related outcomes...
February 12, 2024: Neurology and Therapy
https://read.qxmd.com/read/38329615/long-term-effectiveness-of-galcanezumab-in-the-prevention-of-migraine-an-italian-retrospective-analysis-reality
#17
JOURNAL ARTICLE
Fabrizio Vernieri, Luigi Francesco Iannone, Simona Guerzoni, Antonio Russo, Piero Barbanti, Grazia Sances, Sabina Cevoli, Renata Rao, Carlo Lovati, Anna Ambrosini, Carlotta Buzzoni, Federico Battisti, Laura Vatteone, Steffy Martin Luther King, Federico Torelli
BACKGROUND: Galcanezumab is approved in the European Union (EU) as migraine prophylaxis in adults with at least four migraine days per month. The aim of this retrospective observational study was to evaluate the long-term effectiveness of galcanezumab on migraine-related burdens and its impact on the use of healthcare resources for migraine prophylaxis in an Italian setting. METHODS: This retrospective study was conducted in patients with migraine who initiated treatment with galcanezumab for migraine prevention between September 2019 and December 2020...
February 8, 2024: Neurology and Therapy
https://read.qxmd.com/read/38308801/clinical-and-polysomnographic-characteristics-of-adult-patients-with-suspected-obstructive-sleep-apnea-from-different-sleep-clinics-at-a-single-tertiary-center
#18
JOURNAL ARTICLE
Eunmi Lee, Hyunjo Lee
INTRODUCTION: The characteristics of patients across different sleep clinics may vary because they selectively visit specific specialists on the basis of their primary symptoms. This study aimed to compare the clinical and polysomnography (PSG) features of patients with suspected obstructive sleep apnea (OSA) at three sleep specialty clinics (otolaryngology [ENT], neurology [NR], and psychiatry [PSY]). METHODS: We retrospectively analyzed the medical records and PSG reports of adult patients who underwent full-night PSG between January 2022 and June 2023 at a tertiary medical center...
February 3, 2024: Neurology and Therapy
https://read.qxmd.com/read/38300459/conversion-to-brivaracetam-monotherapy-in-clinical-practice-a-retrospective-study
#19
JOURNAL ARTICLE
Simona Lattanzi, Nicoletta Foschi, Chiara Martellino, Daniela Audenino, Giovanni Boero, Paolo Bonanni, Edoardo Ferlazzo, Valentina Chiesa, Filippo Dainese, Marta Piccioli, Alessandra Ferrari, Angelo Labate
INTRODUCTION: The study aimed to evaluate the effectiveness and safety of brivaracetam (BRV) as conversion monotherapy in adults with focal epilepsy treated in the context of real-world clinical practice. METHODS: This was a retrospective, observational, non-interventional study in adults with focal epilepsy who converted to BRV monotherapy following the withdrawal of background antiseizure medications (ASMs). Primary effectiveness outcome was the retention rate of BRV as single ASM at 6 and 12 months...
February 1, 2024: Neurology and Therapy
https://read.qxmd.com/read/38263492/textbook-outcomes-among-patients-with-aneurysmal-subarachnoid-hemorrhage-following-endovascular-treatment
#20
JOURNAL ARTICLE
Zisheng Liu, Yuhao Tan, Yanpeng Wei, Dongwei Dai, Rui Zhao, Qiang Li, Qinghai Huang, Yi Xu, Pengfei Yang, Jun Sun, Jianmin Liu, Qiao Zuo
INTRODUCTION: The case fatality rate among patients with aneurysmal subarachnoid hemorrhage (aSAH) has decreased progressively, with numerous patients subjected to contemporary paradigms that minimize the use of agonizing therapeutic processes. The concept of the "Textbook Outcome" (TO), a composite outcome that highlights numerous favorable outcomes, was developed in the context of gastrointestinal tumor surgeries and expeditiously extended across diverse surgical spheres. The aim of this study was to explore the factors hindering the achievement of optimal prognoses in postinterventional aSAH patients, employ textbook outcomes, and establish predictive models...
January 23, 2024: Neurology and Therapy
journal
journal
49896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.